Vaxart Inc Stock Price, News & Analysis

Vaxart, Inc. (NASDAQ: VXRT) reported progress in its COVID-19 and norovirus vaccine programs in its second quarter update on August 8, 2022. They are developing vaccine candidates targeting omicron variants and expect top-line Phase II COVID-19 data in Q3 2022. The company ended Q2 with $131.5 million in cash, down from $157.0 million, and reported a net loss of $29.4 million. R&D expenses surged to $19.9 million, reflecting increased investments in vaccine development. The company aims to select COVID-19 constructs in Q4 2022 and start new trials in 2023.

Vaxart, Inc. (Nasdaq: VXRT) announced that all six proposals in its 2022 Proxy Statement were approved at the reconvened Annual Meeting of Stockholders on August 4, 2022. Proposal 2, which increases the authorized shares to 250 million, received 82% support, surpassing the required 50%. Proposals 3 and 4, amendments to the Equity Incentive Plan and the Employee Stock Purchase Plan, were contingent on the passage of Proposal 2. This strong backing reflects stockholder confidence in Vaxart's oral vaccine programs.

Vaxart, Inc. (NASDAQ: VXRT) announced it will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call hosted by senior management will begin at 4:30 p.m. ET to provide a business update and discuss financials. Vaxart is a clinical-stage biotech company focused on developing oral recombinant vaccines for various diseases, including coronavirus and norovirus. The company utilizes a unique tablet delivery system, aiming to enhance vaccine accessibility and safety.

Vaxart, Inc. (Nasdaq: VXRT) announced its request for stockholders to vote on Proxy Proposal #2, which aims to increase authorized shares to 250 million. As of now, 49.1% of shares have voted in favor, needing an additional 0.9% for approval by the August 3, 2022, deadline. Notably, over 80% of the votes cast so far support the proposal, with backing from leading proxy advisory firms ISS and Glass Lewis. CEO Andrei Floroiu emphasized the proposal's importance for business growth and competitive positioning.

Vaxart's recent phase 1 clinical trial data reveals its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induces long-lasting mucosal IgA antibody responses, with effects lasting up to one year. These IgA antibodies exhibited greater neutralizing activity than those from convalescent samples. The study involved 35 healthy participants and confirmed the vaccine's tolerability and immunogenicity. Vaxart aims to leverage these findings for future vaccine candidate development as part of ongoing efforts to address emerging SARS-CoV-2 variants.

Vaxart, Inc. (Nasdaq: VXRT) announced that its Chief Scientific Officer, Dr. Sean Tucker, and Senior Scientist, Dr. Rebecca Flitter, will present data on its COVID-19 oral tablet vaccine at the International Congress of Mucosal Immunology 2022, scheduled for July 16-20 in Seattle. On July 18, Dr. Tucker will discuss oral vaccination's ability to induce pan-coronavirus nasal IgA responses, while Dr. Flitter will present findings on mucosal rAd5 immunization against SARS-CoV-2, showcasing its effectiveness in non-human primates.

Vaxart, Inc. (Nasdaq: VXRT) is urging stockholders to vote on Proxy Proposal #2 by July 5, 2022, which seeks to increase authorized shares to 250 million. This proposal is backed by ISS and Glass Lewis, indicating strong support. Currently, 76% of present voting shares favor the proposal, but it requires more than 50% of all outstanding shares to pass. CEO Andrei Floroiu emphasizes that approval would enhance capital-raising flexibility, aiding Vaxart's promising pipeline and competitive position. Stockholders can vote online, by phone, or via mail.

Vaxart, Inc. (Nasdaq: VXRT) has entered an agreement with hVIVO Services Limited to develop a human challenge model based on the Omicron variant of SARS-CoV-2. This initiative aims to support a Phase II Human Challenge Trial of Vaxart's oral COVID-19 vaccine pill candidate. Vaxart is pioneering the use of an Omicron-specific challenge study, making it the first company to do so. The successful execution of the challenge study is expected to start in 2023, contingent upon regulatory approvals.

Vaxart, Inc. (Nasdaq: VXRT) announced a Q&A webcast with investors and analysts on June 22, 2022, at 1:00 p.m. ET, featuring CEO Andrei Floroiu, SVP Dr. Sean Tucker, and CMO Dr. James Cummings. They will discuss the company's oral vaccine programs and answer submitted questions. The event will be available for replay two hours after its conclusion on Vaxart's website. Additionally, Vaxart’s 2022 annual meeting has been rescheduled to July 6, 2022, at 12:30 p.m. ET, encouraging stockholders to vote by July 5, 2022.